Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical symptoms associated with psoriasis. Its introducti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Villaverde, Ricardo, Rodriguez-Fernandez-Freire, Lourdes, Pérez-Gil, Amalia, Font-Ugalde, Pilar, Galán-Gutiérrez, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697008/
https://www.ncbi.nlm.nih.gov/pubmed/36431015
http://dx.doi.org/10.3390/life12111883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697008/
https://www.ncbi.nlm.nih.gov/pubmed/36431015
http://dx.doi.org/10.3390/life12111883

Ejemplares similares